Fecal M2-PK in Children with Crohn’s Disease: A Preliminary Report
暂无分享,去创建一个
A. Day | D. Lemberg | S. Leach | T. Judd
[1] D. Turner,et al. Update of fecal markers of inflammation in inflammatory bowel disease , 2011, Journal of gastroenterology and hepatology.
[2] A. Griffiths,et al. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response , 2010, Gut.
[3] S. Lewis,et al. Age-related faecal calprotectin, lactoferrin and tumour M2-PK concentrations in healthy volunteers , 2010, Annals of clinical biochemistry.
[4] S. Lewis,et al. Fecal dimeric M2‐pyruvate kinase (tumor M2‐PK) in the differential diagnosis of functional and organic bowel disorders , 2009, Inflammatory bowel diseases.
[5] J. Stockman. Laboratory Values for Children With Newly Diagnosed Inflammatory Bowel Disease , 2009 .
[6] A. Day,et al. Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children , 2008, Inflammatory bowel diseases.
[7] I. Forgacs,et al. Fecal M2‐pyruvate kinase (M2‐PK): A novel marker of intestinal inflammation , 2007, Inflammatory bowel diseases.
[8] K. Herzig,et al. Fecal pyruvate kinase: A potential new marker for intestinal inflammation in children with inflammatory bowel disease , 2007, Scandinavian journal of gastroenterology.
[9] A. Day,et al. Fecal S100A12: A novel noninvasive marker in children with Crohn's disease , 2006, Inflammatory bowel diseases.
[10] N. Afzal,et al. Inflammatory bowel disease , 2006, Archives of Disease in Childhood.
[11] H. Brenner,et al. Tumor M2 pyruvate kinase as a stool marker for colorectal cancer: stability at room temperature and implications for application in the screening setting. , 2006, Clinical chemistry.
[12] A. Michalsen,et al. Comparison of 4 Neutrophil‐Derived Proteins in Feces As Indicators of Disease Activity in Ulcerative Colitis , 2005, Inflammatory bowel diseases.
[13] J. Satsangi,et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[14] M. Drews,et al. Fecal pyruvate kinase (M2-PK): A new predictor for inflammation and severity of pouchitis , 2005, Scandinavian journal of gastroenterology.
[15] E. Eigenbrodt,et al. Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer , 2004, British Journal of Cancer.
[16] S. Ghosh,et al. Is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease? , 2002 .
[17] T. Yao. [Inflammatory bowel diseases]. , 2002, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine.
[18] I. Arnott,et al. Review article: is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease? , 2002, Alimentary pharmacology & therapeutics.
[19] J T Boyle,et al. Development and validation of a pediatric Crohn's disease activity index. , 1991, Journal of pediatric gastroenterology and nutrition.